Contrasting Medline (NASDAQ:MDLN) & Insulet (NASDAQ:PODD)

Medline (NASDAQ:MDLN – Get Free Report) and Insulet (NASDAQ:PODD – Get Free Report) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Medline and Insulet, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medline 2 4 23 0 2.72
Insulet 1 12 12 0 2.44

Medline currently has a consensus target price of $46.08, suggesting a potential upside of 18.40%. Insulet has a consensus target price of $185.67, suggesting a potential upside of 27.47%. Given Insulet’s higher possible upside, analysts clearly believe Insulet is more favorable than Medline.

Profitability

This table compares Medline and Insulet’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Medline 1.84% 8.21% 4.03%
Insulet 13.44% 31.76% 14.48%

Valuation & Earnings

This table compares Medline and Insulet”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Medline $28.43 billion 1.80 $1.16 billion $0.44 88.44
Insulet $3.19 billion 3.17 $247.10 million $6.14 23.72

Medline has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

Summary

Insulet beats Medline on 6 of the 11 factors compared between the two stocks.

About Medline

(Get Free Report)

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.

About Insulet

(Get Free Report)

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.